AbbVie Inc. $ABBV Shares Purchased by Farther Finance Advisors LLC

Farther Finance Advisors LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 89.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 90,459 shares of the company’s stock after purchasing an additional 42,801 shares during the quarter. Farther Finance Advisors LLC’s holdings in AbbVie were worth $20,669,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Chelsea Counsel Co. acquired a new position in AbbVie in the third quarter valued at $26,000. Westend Capital Management LLC acquired a new position in AbbVie in the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the third quarter valued at $31,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter valued at $26,000. Finally, Caitlin John LLC acquired a new position in AbbVie in the third quarter valued at $33,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of ABBV opened at $210.29 on Wednesday. AbbVie Inc. has a fifty-two week low of $168.54 and a fifty-two week high of $244.81. The company has a market capitalization of $371.83 billion, a price-to-earnings ratio of 89.11, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. The firm has a 50-day simple moving average of $219.66 and a 200-day simple moving average of $223.88.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 earnings per share. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Analyst Ratings Changes

Several research firms have issued reports on ABBV. Citigroup decreased their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Cantor Fitzgerald decreased their price objective on AbbVie from $250.00 to $240.00 and set an “overweight” rating for the company in a report on Wednesday, April 8th. Piper Sandler increased their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Guggenheim increased their price objective on AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a report on Friday, April 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.00.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by company insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data showed Elahere (mirvetuximab) demonstrated efficacy and safety in platinum‑sensitive ovarian cancer — news that strengthens AbbVie’s oncology story and could support future uptake/launch value. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie struck an exclusive licensing deal with China’s Haisco for pain assets (deal reported up to ~$715–745M), giving AbbVie global rights outside China and expanding its pain pipeline — a near‑term catalyst for pipeline diversification and future revenue optionality. AbbVie inks $715M deal with Chinese biotech Haisco
• Positive Sentiment: An analyst price target lift to $249 signals bullish sell‑side sentiment and likely supports buying interest. AbbVie (NYSE:ABBV) Price Target Raised to $249.00
• Positive Sentiment: AbbV-438 myeloma Phase 1 update highlights AbbVie’s early‑stage oncology investments — an incremental positive for long‑term oncology growth, though clinical risk remains. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: Analysts and coverage pieces note neuroscience brands (Botox, Vraylar) are expected to help Q1 top‑line performance — supportive but dependent on execution and pricing dynamics. Will AbbVie’s Neuroscience Franchise Aid Top-line Growth in Q1?
• Neutral Sentiment: Coverage on AbbVie entering the weight‑loss arena notes progress but says the company remains behind leaders (e.g., Lilly) — a mixed signal on competitive positioning in metabolic/weight‑loss space. Could AbbVie Crash Lilly’s Weight‑Loss Party?
• Neutral Sentiment: Marketing/aesthetics PR (Natrelle breast‑implant campaign) increases brand visibility for Allergan Aesthetics, useful for the consumer/aesthetics business but unlikely to move fundamentals materially. Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.